Noninvasive biomarker-based risk stratification for development of new onset atrial fibrillation after coronary artery bypass surgery.
Aging
Atrial fibrillation
Biomarkers
Fibrosis
MiR-29
Speckle-tracking echocardiography
Journal
International journal of cardiology
ISSN: 1874-1754
Titre abrégé: Int J Cardiol
Pays: Netherlands
ID NLM: 8200291
Informations de publication
Date de publication:
15 05 2020
15 05 2020
Historique:
received:
15
07
2019
revised:
02
12
2019
accepted:
30
12
2019
pubmed:
19
1
2020
medline:
15
5
2021
entrez:
19
1
2020
Statut:
ppublish
Résumé
Postoperative atrial fibrillation (PoAF) is a common complication after cardiac surgery. A pre-existing atrial substrate appears to be important in postoperative development of dysrhythmia, but its preoperative estimation is challenging. We tested the hypothesis that a combination of clinical predictors, noninvasive surrogate markers for atrial fibrosis defining abnormal left atrial (LA) mechanics, and biomarkers of collagen turnover is superior to clinical predictors alone in identifying patients at-risk for PoAF. In patients without prior AF undergoing coronary artery bypass grafting, concentrations of biomarkers reflecting collagen synthesis and degradation, extracellular matrix, and regulatory microRNA-29s were determined in serum from preoperative blood samples and correlated to atrial fibrosis extent, alteration in atrial deformation properties determined by 3D speckle-tracking echocardiography, and AF development. Of 90 patients without prior AF, 34 who developed PoAF were older than non-PoAF patients (72.04 ± 10.7 y; P = 0.043) with no significant difference in baseline comorbidities, LA size, or ventricular function. Global (P = 0.007) and regional longitudinal LA strain and ejection fraction (P = 0.01) were reduced in PoAF vs. non-PoAF patients. Preoperative amino-terminal-procollagen-III-peptide (PIIINP) (103.1 ± 39.7 vs. 35.1 ± 19.3; P = 0.041) and carboxy-terminal-procollagen-I-peptide levels were elevated in PoAF vs. non-PoAF patients with a reduction in miR-29 levels and correlated with atrial fibrosis extent. Combining age as the only significant clinical predictor with PIIINP and miR-29a provided a model that identified PoAF patients with higher predictive accuracy. In patients without a previous history of AF, using age and biomarkers of collagen synthesis and regulation, a noninvasive tool was developed to identify those at risk for new-onset PoAF.
Sections du résumé
BACKGROUND
Postoperative atrial fibrillation (PoAF) is a common complication after cardiac surgery. A pre-existing atrial substrate appears to be important in postoperative development of dysrhythmia, but its preoperative estimation is challenging. We tested the hypothesis that a combination of clinical predictors, noninvasive surrogate markers for atrial fibrosis defining abnormal left atrial (LA) mechanics, and biomarkers of collagen turnover is superior to clinical predictors alone in identifying patients at-risk for PoAF.
METHODS
In patients without prior AF undergoing coronary artery bypass grafting, concentrations of biomarkers reflecting collagen synthesis and degradation, extracellular matrix, and regulatory microRNA-29s were determined in serum from preoperative blood samples and correlated to atrial fibrosis extent, alteration in atrial deformation properties determined by 3D speckle-tracking echocardiography, and AF development.
RESULTS
Of 90 patients without prior AF, 34 who developed PoAF were older than non-PoAF patients (72.04 ± 10.7 y; P = 0.043) with no significant difference in baseline comorbidities, LA size, or ventricular function. Global (P = 0.007) and regional longitudinal LA strain and ejection fraction (P = 0.01) were reduced in PoAF vs. non-PoAF patients. Preoperative amino-terminal-procollagen-III-peptide (PIIINP) (103.1 ± 39.7 vs. 35.1 ± 19.3; P = 0.041) and carboxy-terminal-procollagen-I-peptide levels were elevated in PoAF vs. non-PoAF patients with a reduction in miR-29 levels and correlated with atrial fibrosis extent. Combining age as the only significant clinical predictor with PIIINP and miR-29a provided a model that identified PoAF patients with higher predictive accuracy.
CONCLUSIONS
In patients without a previous history of AF, using age and biomarkers of collagen synthesis and regulation, a noninvasive tool was developed to identify those at risk for new-onset PoAF.
Identifiants
pubmed: 31952855
pii: S0167-5273(19)33407-2
doi: 10.1016/j.ijcard.2019.12.067
pmc: PMC8011128
mid: NIHMS1549895
pii:
doi:
Substances chimiques
Biomarkers
0
MIRN29a microRNA, human
0
MicroRNAs
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
55-62Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL101240
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest None.
Références
J Thorac Cardiovasc Surg. 2011 Feb;141(2):559-70
pubmed: 20434173
J Am Coll Cardiol. 2008 Jul 15;52(3):211-5
pubmed: 18617070
J Card Surg. 2007 Mar-Apr;22(2):117-23
pubmed: 17338744
JAMA. 2004 Apr 14;291(14):1720-9
pubmed: 15082699
Europace. 2012 Feb;14(2):159-74
pubmed: 21821851
World J Surg. 2014 Jan;38(1):51-9
pubmed: 24129801
J Interv Card Electrophysiol. 2011 Sep;31(3):197-206
pubmed: 21424845
Sci Rep. 2017 Jan 12;7:40378
pubmed: 28079145
Circulation. 2011 Nov 1;124(18):1982-93
pubmed: 22042927
Circ Cardiovasc Imaging. 2010 May;3(3):231-9
pubmed: 20133512
Nat Commun. 2017 Nov 20;8(1):1614
pubmed: 29158499
Circulation. 2018 Mar 20;137(12):e67-e492
pubmed: 29386200
Physiol Rev. 2011 Jan;91(1):265-325
pubmed: 21248168
Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):13027-32
pubmed: 18723672
Am J Physiol Cell Physiol. 2016 Aug 1;311(2):C330-9
pubmed: 27335167
JACC Cardiovasc Imaging. 2019 Jun;12(6):981-989
pubmed: 29454773
Eur J Cardiothorac Surg. 2014 Apr;45(4):733-8
pubmed: 24163361
J Am Coll Cardiol. 2004 Jul 7;44(1):109-16
pubmed: 15234418
Clin Res Cardiol. 2012 Aug;101(8):655-61
pubmed: 22407460
PLoS One. 2013;8(3):e59052
pubmed: 23554968
Circulation. 2000 Apr 11;101(14):1729-35
pubmed: 10758057
J Am Soc Echocardiogr. 2017 Oct;30(10):956-965.e1
pubmed: 28987158
Biol Open. 2017 Mar 15;6(3):326-332
pubmed: 28126709
J Am Coll Cardiol. 2014 Mar 11;63(9):920-7
pubmed: 24161319
Eur Heart J. 2016 Oct 7;37(38):2893-2962
pubmed: 27567408
Eur Heart J Cardiovasc Imaging. 2019 Feb 1;20(2):177-184
pubmed: 29608669
Circulation. 2011 Jul 19;124(3):363-72
pubmed: 21709057
J Am Coll Cardiol. 2012 Oct 30;60(18):1799-806
pubmed: 23040566
Eur J Clin Invest. 2015 Feb;45(2):170-8
pubmed: 25510286
Am J Cardiol. 2018 Aug 15;122(4):584-591
pubmed: 30049466
J Am Coll Cardiol. 2008 Feb 26;51(8):793-801
pubmed: 18294562
Ann Thorac Surg. 2007 Oct;84(4):1166-72; discussion 1172-3
pubmed: 17888965
J Am Coll Cardiol. 2014 Jun 3;63(21):2177-87
pubmed: 24583309
Interact Cardiovasc Thorac Surg. 2018 Mar 1;26(3):504-511
pubmed: 29161419
Europace. 2007 Aug;9(8):589-96
pubmed: 17485436
Curr Cardiol Rep. 2018 Aug 27;20(10):96
pubmed: 30151628
Circulation. 2013 Apr 9;127(14):1466-75, 1475e1-28
pubmed: 23459615
Nat Rev Cardiol. 2015 Feb;12(2):80-90
pubmed: 25421165
Cardiol Rev. 2016 Mar-Apr;24(2):76-87
pubmed: 25699982
Heart Lung Circ. 2016 Oct;25(10):993-9
pubmed: 27011039